Loading...
Market
What will be Syndax Pharmaceuticals' revenue growth rate in 2025?
3
Resolution / Starting Odds
Less than 5% growth • 25%
5% to 10% growth • 25%
10% to 20% growth • 25%
More than 20% growth • 25%
Syndax Pharmaceuticals' annual financial reports
Story
FDA Approves Syndax's Revuforj for Acute Leukemia, Shares Rise 4%
Nov 15, 2024, 10:53 PM
The U.S. Food and Drug Administration (FDA) has approved Revuforj (revumenib), developed by Syndax Pharmaceuticals, for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation. This approval, announced on Friday, is significant as Revuforj is the first and only menin inhibitor to treat this specific type of leukemia. The drug is approved for both adult and pediatric patients one year and older. Following the announcement, Syndax Pharmaceuticals' shares rose by 4% in after-hours trading.
View original story
Similar markets
No change • 25%
Improved by 1-5 ranks • 25%
Improved by 6-10 ranks • 25%
Improved by more than 10 ranks • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
More than 20% increase • 25%
10%-20% increase • 25%
0%-10% increase • 25%
Decrease • 25%
Increase by more than 20% • 25%
Increase by 10-20% • 25%
Increase by less than 10% • 25%
No increase or decrease • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Below 10% • 25%
10% to 15% • 25%
15% to 20% • 25%
Above 20% • 25%